secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001193125-23-029218
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen appoints Martin D. Madaus to board; board expands to 8
---------------------------------------------------------------

- Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.
- Board size increased from seven to eight directors upon Madaus' election.
- Madaus received initial option grant valued at $170,000, vesting equally over three years.
- Pro-rata equity award of options and RSUs each valued at $21,250, vesting at next annual shareholder meeting.
- Madaus brings over 25 years of life sciences tools industry experience, including CEO roles at Millipore and Ortho Clinical Diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/0001193125-23-029218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/d802605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-029218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer